Ensuring ACCESS TO SAFE AND EFFECTIVE MEDICINES FOR ALL is a complex challenge that requires innovation and collaboration.
Ensuring ACCESS TO SAFE AND EFFECTIVE MEDICINES FOR ALL is a complex challenge that requires innovation and collaboration.
Ensuring ACCESS TO SAFE AND EFFECTIVE MEDICINES FOR ALL is a complex challenge that requires innovation and collaboration.
MIT CBI is a COLLABORATION ENGINE that brings together the excellence of MIT researchers with stakeholders across the healthcare value chain.
MIT CBI is a COLLABORATION ENGINE that brings together the excellence of MIT researchers with stakeholders across the healthcare value chain.
MIT CBI is a COLLABORATION ENGINE that brings together the excellence of MIT researchers with stakeholders across the healthcare value chain.
Collaboratively, MIT CBI DESIGNS, TESTS, and IMPLEMENTS ways to ensure global access to safe and effective medicines.
Collaboratively, MIT CBI DESIGNS, TESTS, and IMPLEMENTS ways to ensure global access to safe and effective medicines.
Collaboratively, MIT CBI DESIGNS, TESTS, and IMPLEMENTS ways to ensure global access to safe and effective medicines.
MIT CBI is home to the Biomanufacturing Consortium (BioMAN), and the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB). These pre-competitive programs provide a safe haven where industry, academia, and government collaboratively address challenges in manufacturing, delivery, and access to biologics through focused events and projects that address key challenges in biomanufacturing.
MIT CBI research projects focus on biomanufacturing process innovation for production of biologic medicines including monoclonal antibodies, vaccines, viral vectors, and cell therapies. Our main research areas include process analytical technologies, biomanufacturing data analytics, advanced process modeling and control, and continuous manufacturing.
MIT CBI has developed a number of biomanufacturing-related educational offerings including a residential MIT course, an on-line course on the principles of manufacturing protein and antibody drugs, and a short course on vaccine manufacturing offered jointly with University College London. We have developed a blended learning course for the training of cell therapy manufacturing personnel which will combine online learning with hands-on training.
Our members and collaborators are leading stakeholders across the global healthcare value chain,
from research and development, manufacturing, delivery, and clinical care.
